Recently Featured

Prophylactic Phage Therapy Protects Mice Against Oral Salmonella Infection

October 6, 2026
Researchers at Virginia Tech have successfully developed a prophylactic phage therapy that protects mice from oral infections caused by Salmonella enterica Typhimurium (STm). This innovative approach involves engineering a nonpathogenic Escherichia coli strain that produces bacteriophages specifically targeting STm, thereby enhancing survival rates in mouse models of STm-induced colitis. The study, led by Dr. Bryan…

Cellares and GenomeFrontier Therapeutics Partner to Advance Automated Manufacturing of GF-CART01

October 6, 2026
Cellares, an integrated development and manufacturing organization (IDMO), has formed a partnership with GenomeFrontier Therapeutics, a Taiwanese company focused on virus-free CAR T therapies, to enhance the automated manufacturing of GF-CART01, GenomeFrontier’s investigational CAR T-cell therapy, utilizing Cellares’ Cell Shuttle platform. This collaboration aims to translate GenomeFrontier’s manufacturing processes to the Cell Shuttle, particularly focusing…

FDA Clarifies Policies for Compounders as National GLP-1 Supply Begins to Stabilize

October 6, 2026
The U.S. Food and Drug Administration has announced that the shortage of tirzepatide injection, a critical glucagon-like peptide 1 (GLP-1) medication, is now resolved. This shortage, which persisted since 2022, was primarily driven by a surge in demand for weight management and diabetes treatment options. The FDA’s clarification of policies regarding compounders comes at a…

Prime Assembly Expands Genome Editing with Precise, Large-Scale DNA Integration

October 6, 2026
A novel genome engineering method, known as prime assembly, is set to revolutionize genome editing by enabling the precise integration of long DNA fragments at targeted locations within living cells. This advancement addresses the limitations of current genome editing techniques, which often rely on untargeted gene delivery and short DNA edits tailored to individual patients.…

Ongoing Cases